<DOC>
	<DOCNO>NCT00722293</DOCNO>
	<brief_summary>This open-label , four-arm , Phase I , dose escalation study evaluate safety tolerability determine optimal tolerate regimen ( OTR ) pazopanib combination epirubicin doxorubicin patient advance solid tumor . Patients enrol cohort 3 receive escalating dos pazopanib epirubicin doxorubicin . Dose escalation schema study arm describe protocol . For arm , OTR define high dose combination agent one six patient experience dose-limiting toxicity . Twelve additional patient arm study OTR evaluate toxicity pharmacokinetics . This allow assessment potential drug-drug interaction . Antitumor activity assess use RECIST criterion .</brief_summary>
	<brief_title>A Phase I , Open-label , Study Pazopanib Combination With Epirubicin Doxorubicin Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Patients must provide write informed consent prior performance study specific procedure assessment , must willing comply treatment follow Histologically cytologically confirm diagnosis advance solid tumor fail standard therapy standard therapy indicate treatment anthracyclines . Age great equal 18 year . Adequate organ system function define protocol . ECOG performance value 0 1 . Less equal one prior line chemotherapy advance disease . Patients metastatic disease brain definitive therapy brain metastasis , asymptomatic . ( Patients previously treat brain metastasis asymptomatic , steroids antiseizure medication great 3 month eligible study ) . There must measurable disease evaluable disease subject include cohort expansion phase . Measurable disease criterion subject enrol dose escalation phase . Has leave ventricular ejection fraction ( LVEF ) great equal 50 % great equal institution 's LLN . Women childbearing potential must negative pregnancy test within 2 week start study drug use acceptable birth control method outline protocol . Women may participate non childbearing potential ( bilateral tubal ligation , hysterectomy , post menopausal bilateral ovariectomy . Males female partner childbearing potential may participate practice acceptable method birth control outline study protocol . Able swallow retain oral medication . Less equal one prior line chemotherapy advance disease . Life expectancy least 12 week . Prior use pazopanib prior treatment anthracyclines . Prior therapy angiogenesis inhibitor permit . Clinically significant gastrointestinal abnormality might interfere oral dosing . Any unstable serious concurrent condition ( e.g. , active infection require systemic therapy ) . QTc &gt; 480 msec . History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting Myocardial infarction Unstable angina Symptomatic peripheral vascular disease Class III IV congestive heart failure Any major surgery trauma within last 28 day presence nonhealing wound , fracture , ulcer . Any unstable serious concurrent condition . Poorly control hypertension [ define systolic blood pressure ( SBP ) =140mmHg diastolic blood pressure ( DBP ) = 90mmHg ] . History cerebrovascular accident ( CVA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Subjects recent DVT treat therapeutic agent ( exclude therapeutic warfarin ) least 6 week eligible . Prior major surgery trauma within 28 day prior first dose study drug /or presence nonhealing wound , fracture , ulcer . Hemoptysis within 6 week prior first dose study drug . Any serious and/or unstable preexist medical , psychiatric , condition could interfere patient 's safety , provision inform consent , compliance study procedure . Is unable unwilling discontinue prohibit medication 14 day five halflives drug prior Visit 1 duration study . Use investigational agent , include investigational anticancer agent , within 28 day 5 halflives , whichever longer , prior first dose study drug . Is undergo and/or undergone within 28 day immediately prior first dose study drug , cancer therapy ( major surgery , investigational agent , tumor embolization , chemotherapy , radiation therapy , immunotherapy , biological therapy , hormonal therapy ) . Clinically assess inadequate venous access PK sampling . Lactating pregnant woman discontinue lactation prior first use study drug refrain nursing throughout treatment period 14 day final dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>Cancer</keyword>
	<keyword>Neoplasms , Ovarian</keyword>
	<keyword>doxorubicin</keyword>
	<keyword>epirubicin</keyword>
	<keyword>anti-angiogenesis</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>pazopanib ( GW786034 )</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Soft Tissue</keyword>
	<keyword>Sarcoma</keyword>
</DOC>